Non-obese histologically confirmed NASH patients with abnormal liver biochemistry have more advanced fibrosis

Qianyi Wang, Hong You, Xiaojuan Ou, Xinyan Zhao, Yameng Sun, Min Wang, Ping Wang, Yu Wang, Weijia Duan, Xiaoming Wang, Shanshan Wu, Yuanyuan Kong, Romil Saxena, Annette S.H. Gouw, Jidong Jia

Research output: Contribution to journalArticle

Abstract

Background and aims: Non-alcoholic fatty liver disease (NAFLD) commonly affects subjects with obesity, yet non-obese NAFLD is increasingly being recognized. We aimed to investigate the clinicopathological and genetic characteristics of non-obese NAFLD patients. Methods: The clinical, histological and genetic data of 84 NAFLD patients with biopsy for abnormal liver function test were reviewed. Both NAS-CRN and SAF scoring systems were applied for histopathological evaluation. PNPLA3 and TMS6F2 genotyping were also performed. Results: All of the 84 patients were histologically diagnosed with non-alcoholic steatohepatitis (NASH), with 36 of them (42.9%) being non-obese (BMI < 25 kg/m2). Compared with the obese group, non-obese group were predominantly females (88.9% vs 52.1%, p < 0.001), tended to have higher prevalence of diabetes (p = 0.068). More importantly non-obese patients had a significant higher prevalence of advanced fibrosis (F ≥ 3) (58.3% vs 29.2%, p = 0.013), and a trend of higher degree of ballooning (p = 0.061). In addition, values of liver stiffness measurement were also significantly higher in non-obese group (12.1 kPa vs 8.1 kPa, p = 0.032). There was also a trend of higher prevalence of TM6SF2 T allele in non-obese group (p = 0.085), while the prevalence of PNPLA3 risk allele did not differ between two groups. Multivariate analysis showed that higher fasting glucose (p = 0.038) and lower serum platelets (p = 0.040) were two independent predictors for advanced fibrosis in non-obese patients. Conclusions: Non-obese NASH patients have a female predominance and more advanced fibrosis. Liver biopsy is crucial to evaluate the severity of disease in non-obese patients especially those with abnormal liver biochemistry. Clinical trial number: NCT03386890.

Original languageEnglish (US)
JournalHepatology International
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Fatty Liver
Biochemistry
Fibrosis
Liver
Alleles
Biopsy
Liver Function Tests
Fasting
Blood Platelets
Multivariate Analysis
Obesity
Clinical Trials
Glucose
Non-alcoholic Fatty Liver Disease
Serum

Keywords

  • Hepatic fibrosis
  • Non-alcoholic fatty liver disease
  • Non-alcoholic steatohepatitis
  • Non-obese

ASJC Scopus subject areas

  • Hepatology

Cite this

Non-obese histologically confirmed NASH patients with abnormal liver biochemistry have more advanced fibrosis. / Wang, Qianyi; You, Hong; Ou, Xiaojuan; Zhao, Xinyan; Sun, Yameng; Wang, Min; Wang, Ping; Wang, Yu; Duan, Weijia; Wang, Xiaoming; Wu, Shanshan; Kong, Yuanyuan; Saxena, Romil; Gouw, Annette S.H.; Jia, Jidong.

In: Hepatology International, 01.01.2019.

Research output: Contribution to journalArticle

Wang, Q, You, H, Ou, X, Zhao, X, Sun, Y, Wang, M, Wang, P, Wang, Y, Duan, W, Wang, X, Wu, S, Kong, Y, Saxena, R, Gouw, ASH & Jia, J 2019, 'Non-obese histologically confirmed NASH patients with abnormal liver biochemistry have more advanced fibrosis', Hepatology International. https://doi.org/10.1007/s12072-019-09982-z
Wang, Qianyi ; You, Hong ; Ou, Xiaojuan ; Zhao, Xinyan ; Sun, Yameng ; Wang, Min ; Wang, Ping ; Wang, Yu ; Duan, Weijia ; Wang, Xiaoming ; Wu, Shanshan ; Kong, Yuanyuan ; Saxena, Romil ; Gouw, Annette S.H. ; Jia, Jidong. / Non-obese histologically confirmed NASH patients with abnormal liver biochemistry have more advanced fibrosis. In: Hepatology International. 2019.
@article{5b155665735b46c9a03edc039f9cb305,
title = "Non-obese histologically confirmed NASH patients with abnormal liver biochemistry have more advanced fibrosis",
abstract = "Background and aims: Non-alcoholic fatty liver disease (NAFLD) commonly affects subjects with obesity, yet non-obese NAFLD is increasingly being recognized. We aimed to investigate the clinicopathological and genetic characteristics of non-obese NAFLD patients. Methods: The clinical, histological and genetic data of 84 NAFLD patients with biopsy for abnormal liver function test were reviewed. Both NAS-CRN and SAF scoring systems were applied for histopathological evaluation. PNPLA3 and TMS6F2 genotyping were also performed. Results: All of the 84 patients were histologically diagnosed with non-alcoholic steatohepatitis (NASH), with 36 of them (42.9{\%}) being non-obese (BMI < 25 kg/m2). Compared with the obese group, non-obese group were predominantly females (88.9{\%} vs 52.1{\%}, p < 0.001), tended to have higher prevalence of diabetes (p = 0.068). More importantly non-obese patients had a significant higher prevalence of advanced fibrosis (F ≥ 3) (58.3{\%} vs 29.2{\%}, p = 0.013), and a trend of higher degree of ballooning (p = 0.061). In addition, values of liver stiffness measurement were also significantly higher in non-obese group (12.1 kPa vs 8.1 kPa, p = 0.032). There was also a trend of higher prevalence of TM6SF2 T allele in non-obese group (p = 0.085), while the prevalence of PNPLA3 risk allele did not differ between two groups. Multivariate analysis showed that higher fasting glucose (p = 0.038) and lower serum platelets (p = 0.040) were two independent predictors for advanced fibrosis in non-obese patients. Conclusions: Non-obese NASH patients have a female predominance and more advanced fibrosis. Liver biopsy is crucial to evaluate the severity of disease in non-obese patients especially those with abnormal liver biochemistry. Clinical trial number: NCT03386890.",
keywords = "Hepatic fibrosis, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis, Non-obese",
author = "Qianyi Wang and Hong You and Xiaojuan Ou and Xinyan Zhao and Yameng Sun and Min Wang and Ping Wang and Yu Wang and Weijia Duan and Xiaoming Wang and Shanshan Wu and Yuanyuan Kong and Romil Saxena and Gouw, {Annette S.H.} and Jidong Jia",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s12072-019-09982-z",
language = "English (US)",
journal = "Hepatology International",
issn = "1936-0533",
publisher = "Springer New York",

}

TY - JOUR

T1 - Non-obese histologically confirmed NASH patients with abnormal liver biochemistry have more advanced fibrosis

AU - Wang, Qianyi

AU - You, Hong

AU - Ou, Xiaojuan

AU - Zhao, Xinyan

AU - Sun, Yameng

AU - Wang, Min

AU - Wang, Ping

AU - Wang, Yu

AU - Duan, Weijia

AU - Wang, Xiaoming

AU - Wu, Shanshan

AU - Kong, Yuanyuan

AU - Saxena, Romil

AU - Gouw, Annette S.H.

AU - Jia, Jidong

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background and aims: Non-alcoholic fatty liver disease (NAFLD) commonly affects subjects with obesity, yet non-obese NAFLD is increasingly being recognized. We aimed to investigate the clinicopathological and genetic characteristics of non-obese NAFLD patients. Methods: The clinical, histological and genetic data of 84 NAFLD patients with biopsy for abnormal liver function test were reviewed. Both NAS-CRN and SAF scoring systems were applied for histopathological evaluation. PNPLA3 and TMS6F2 genotyping were also performed. Results: All of the 84 patients were histologically diagnosed with non-alcoholic steatohepatitis (NASH), with 36 of them (42.9%) being non-obese (BMI < 25 kg/m2). Compared with the obese group, non-obese group were predominantly females (88.9% vs 52.1%, p < 0.001), tended to have higher prevalence of diabetes (p = 0.068). More importantly non-obese patients had a significant higher prevalence of advanced fibrosis (F ≥ 3) (58.3% vs 29.2%, p = 0.013), and a trend of higher degree of ballooning (p = 0.061). In addition, values of liver stiffness measurement were also significantly higher in non-obese group (12.1 kPa vs 8.1 kPa, p = 0.032). There was also a trend of higher prevalence of TM6SF2 T allele in non-obese group (p = 0.085), while the prevalence of PNPLA3 risk allele did not differ between two groups. Multivariate analysis showed that higher fasting glucose (p = 0.038) and lower serum platelets (p = 0.040) were two independent predictors for advanced fibrosis in non-obese patients. Conclusions: Non-obese NASH patients have a female predominance and more advanced fibrosis. Liver biopsy is crucial to evaluate the severity of disease in non-obese patients especially those with abnormal liver biochemistry. Clinical trial number: NCT03386890.

AB - Background and aims: Non-alcoholic fatty liver disease (NAFLD) commonly affects subjects with obesity, yet non-obese NAFLD is increasingly being recognized. We aimed to investigate the clinicopathological and genetic characteristics of non-obese NAFLD patients. Methods: The clinical, histological and genetic data of 84 NAFLD patients with biopsy for abnormal liver function test were reviewed. Both NAS-CRN and SAF scoring systems were applied for histopathological evaluation. PNPLA3 and TMS6F2 genotyping were also performed. Results: All of the 84 patients were histologically diagnosed with non-alcoholic steatohepatitis (NASH), with 36 of them (42.9%) being non-obese (BMI < 25 kg/m2). Compared with the obese group, non-obese group were predominantly females (88.9% vs 52.1%, p < 0.001), tended to have higher prevalence of diabetes (p = 0.068). More importantly non-obese patients had a significant higher prevalence of advanced fibrosis (F ≥ 3) (58.3% vs 29.2%, p = 0.013), and a trend of higher degree of ballooning (p = 0.061). In addition, values of liver stiffness measurement were also significantly higher in non-obese group (12.1 kPa vs 8.1 kPa, p = 0.032). There was also a trend of higher prevalence of TM6SF2 T allele in non-obese group (p = 0.085), while the prevalence of PNPLA3 risk allele did not differ between two groups. Multivariate analysis showed that higher fasting glucose (p = 0.038) and lower serum platelets (p = 0.040) were two independent predictors for advanced fibrosis in non-obese patients. Conclusions: Non-obese NASH patients have a female predominance and more advanced fibrosis. Liver biopsy is crucial to evaluate the severity of disease in non-obese patients especially those with abnormal liver biochemistry. Clinical trial number: NCT03386890.

KW - Hepatic fibrosis

KW - Non-alcoholic fatty liver disease

KW - Non-alcoholic steatohepatitis

KW - Non-obese

UR - http://www.scopus.com/inward/record.url?scp=85074000657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074000657&partnerID=8YFLogxK

U2 - 10.1007/s12072-019-09982-z

DO - 10.1007/s12072-019-09982-z

M3 - Article

C2 - 31559605

AN - SCOPUS:85074000657

JO - Hepatology International

JF - Hepatology International

SN - 1936-0533

ER -